List view / Grid view
The unveiling of the new technology centre in Biberach represents…
8 December 2014 | By Boehringer Ingelheim
The unveiling of the new technology centre in Biberach represents the temporary completion of a remodelling and construction phase in chemical development at Boehringer Ingelheim’s largest research and development location...
The research-driven pharmaceutical company Boehringer Ingelheim overcame major challenges in…
11 August 2014 | By Boehringer Ingelheim
The research-driven pharmaceutical company Boehringer Ingelheim overcame major challenges in the first half of 2014...
The research-driven pharmaceutical company Boehringer Ingelheim is pleased with the…
15 April 2014 | By Boehringer Ingelheim
The research-driven pharmaceutical company Boehringer Ingelheim is pleased with the 2013 financial year...
Boehringer Ingelheim grew further in the first half of 2013,…
14 August 2013 | By Boehringer Ingelheim
Boehringer Ingelheim grew further in the first half of 2013, despite difficult overall conditions...
“We were thrilled by the level of innovation...”
10 July 2013 | By Boehringer Ingelheim
“We were thrilled by the level of innovation...”
Boehringer Ingelheim has grown again in the current financial year...
14 August 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has grown again in the current financial year...
Boehringer Ingelheim is establishing a new 50 million-plus euro pilot…
31 May 2012 | By Boehringer Ingelheim
Boehringer Ingelheim is establishing a new 50 million-plus euro pilot plant facility...
The pharmaceutical company Boehringer Ingelheim has in the first half…
9 August 2011 | By Boehringer Ingelheim
The pharmaceutical company Boehringer Ingelheim has in the first half of 2011 once again grown in local currency terms compared to the previous year (+ 4 percent). Due to negative foreign exchange effects, consolidation in euros shows growth of 2.6 percent, with total net sales of EUR 6.4 billion against…
Pradaxa®1 (dabigatran etexilate) approved...
4 August 2011 | By Ogilvy Healthworld UK Limited
Pradaxa®1 (dabigatran etexilate) approved...
Global agreement will lead to joint development of diabetes compounds…
11 January 2011 | By Eli Lilly and Company
Global agreement will lead to joint development of diabetes compounds currently in mid- and late-stage development...
